drugset / Trial / NCT02062827
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Phase 1
Active not recruiting
29 enrolled
University of Alabama at Birmingham
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simples Virus-1 in patients who would benefit from surgical resection of recurrent glioma
Timeline
- Start
- 2013-11-25
- Primary completion
- 2022-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M032 | Unknown | — | Other |